January 12, 2021 -- Although immuno-oncology therapies have been around for many years, investors are excited to partner with innovators in the space who can push the boundaries of what these therapies are able to achieve. A panel of investors and business development executives discussed what exactly makes a specific candidate attractive as a business opportunity during a recorded session at the Biotech Showcase virtual event.
Immuno-oncology therapies are set to have another exciting year in 2021. These molecules have seen waves of interest for the last two decades, but are finally making progress toward clinical use and reaching patient populations. From checkpoint inhibitors and antibody-based therapies to chimeric antigen receptor (CAR) T-cell therapies, innovation is happening at a rapid pace.
